Remepy has raised $36 million in Series A funding to expand its Hybrid Drug pipeline, accelerate pharmaceutical partnerships, and fund global Phase III development of Hybridopa for Parkinson’s disease. The financing brings the company’s total capital raised to $62 million. O.G. Venture Partners and M Ventures, the strategic venture arm of Merck KGaA, Darmstadt, Germany, led the round. Investors also included NFX, Vine Ventures, Qumra Capital, TechAviv, 97212 Ventures, Fresh Fund, PsyMed Ventures, Tadmor Group, Key1 Capital, and IT-Farm.
Remepy is developing what it calls Hybrid Drugs, which combine prescription medicines with personalized AI-driven therapeutic applications. The approach combines pharmacology with adaptive physical, cognitive, and behavioral interventions through a standard prescription model.
The company has also entered a strategic collaboration with Merck KGaA to develop Hybrid Drugs across multiple indications, beginning with rare tumors.
Remepy’s lead program, Hybridopa, is being developed for Parkinson’s disease. The company said its Phase IIa results demonstrated improvements in motor and non-motor symptoms and were supported by peer-reviewed research into the biological mechanisms behind the treatment.
Global Phase III development is scheduled to begin in the fourth quarter of 2026. Hybridopa remains investigational and has not been approved by the FDA.
KEY QUOTES:
“We believe medicine is entering a new era, where every breakthrough drug will be paired with personalized intelligence to maximize its impact for every patient. Over the past year, we’ve demonstrated that this vision is achievable through clinical validation, peer-reviewed science, regulatory alignment, and partnerships with leading pharmaceutical companies. This financing allows us to advance Phase III of Hybridopa for Parkinson’s disease, and expand the Hybrid Drug model across multiple therapeutic areas.”
Michal Tsur, Ph.D., and Or Shoval, Co-CEOs of Remepy
“We’re excited to lead Remepy’s Series A and support an exceptional team pioneering a new category of medicine. By bringing together biotechnology, AI, and digital health, Remepy is redefining how medicines are developed and delivered. With compelling clinical data, growing regulatory momentum, and strong validation from leading pharmaceutical partners, we believe Hybrid Drugs have the potential to transform patient care.”
Ziv Kop, Managing Partner at O.G. Venture Partners
“Remepy’s pioneering Hybrid Drugs approach reflects the growing importance and applicability of integrating AI into the delivery of health and physical medicines. Our investment from M Ventures is intended to further enable the company, underscoring our belief that this new class of medicine, that combines innovative therapeutics with AI-driven, patient-centered care, has the potential to redefine medicine.”
Dr. Eyal Ben Ami, Scientific Lead at M Ventures
